Artivion Inc

AORT is in an early Stage 1 consolidation and qualifies for mean-reversion, supported by an active Lockout Rally pattern driving urgency-led upside. Medium-term directional asymmetry is bullish under base repair dynamics, and short-term conditions are favorable with price tracking above rising EMAs without exhaustion. Initiate participation now, watching the EMAs as support.

• ↑Q1 2026 revenue $116.3M (+12% YoY) and adjusted EBITDA $22.1M (+26% YoY).
• ↑FDA PMA approval for AMDS mid-year removes IRB, unlocking $150M market.
• ↓Shares trade at 99.6x P/E, indicating high valuation risk.